Show simple item record

Effects of Interleukin-1 beta Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk A Secondary Analysis of CANTOS

dc.contributor.authorRothman, Alexander M. K.
dc.contributor.authorMacFadyen, Jean
dc.contributor.authorThuren, Tom
dc.contributor.authorWebb, Alastair
dc.contributor.authorHarrison, David G.
dc.contributor.authorGuzik, Tomasz J.
dc.contributor.authorLibby, Peter
dc.contributor.authorGlynn, Robert J.
dc.contributor.authorRidker, Paul M.
dc.identifier.citationRothman, A. M., MacFadyen, J., Thuren, T., Webb, A., Harrison, D. G., Guzik, T. J., Libby, P., Glynn, R. J., & Ridker, P. M. (2020). Effects of Interleukin-1β Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk: A Secondary Analysis of CANTOS. Hypertension (Dallas, Tex. : 1979), 75(2), 477–482.
dc.description.abstractWhile hypertension and inflammation are physiologically inter-related, the effect of therapies that specifically target inflammation on blood pressure is uncertain. The recent CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) afforded the opportunity to test whether IL (interleukin)-1 beta inhibition would reduce blood pressure, prevent incident hypertension, and modify relationships between hypertension and cardiovascular events. CANTOS randomized 10 061 patients with prior myocardial infarction and hsCRP (high sensitivity C-reactive protein) >= 2 mg/L to canakinumab 50 mg, 150 mg, 300 mg, or placebo. A total of 9549 trial participants had blood pressure recordings during follow-up; of these, 80% had a preexisting diagnosis of hypertension. In patients without baseline hypertension, rates of incident hypertension were 23.4, 26.6, and 28.1 per 100-person years for the lowest to highest baseline tertiles of hsCRP (P>0.2). In all participants random allocation to canakinumab did not reduce blood pressure (P>0.2) or incident hypertension during the follow-up period (hazard ratio, 0.96 [0.85-1.08], P>0.2). IL-1 beta inhibition with canakinumab reduces major adverse cardiovascular event rates. These analyses suggest that the mechanisms underlying this benefit are not related to changes in blood pressure or incident hypertension.en_US
dc.description.sponsorshipThe investigator-driven CANTOS (Canakinumab Anti-inflammatory Thrombosis Outcomes Study) trial was funded by Novartis. A.M.K. Rothman and A. Webb are supported by Clinical Research Career Development Fellowships from the Wellcome Trust (A.M.K. Rothman: 206632/Z/17/Z; A. Webb: 206589/Z/17/Z).en_US
dc.rightsCopyright © 2019 The Authors. Hypertension is published on behalf of the American Heart Association, Inc., by Wolters Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited.
dc.subjectblood pressureen_US
dc.subjectmyocardial infarctionen_US
dc.titleEffects of Interleukin-1 beta Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk A Secondary Analysis of CANTOSen_US

Files in this item


This item appears in the following Collection(s)

Show simple item record